デフォルト表紙
市場調査レポート
商品コード
1405913

イムノアッセイの市場規模、シェア、動向分析レポート:製品別、技術別、用途別、検体別、最終用途別、地域別、セグメント予測、2024年~2030年

Immunoassay Market Size, Share & Trends Analysis Report By Product (Reagent & Kits, Analyzers/Instruments), By Technology (RIA, ELISA), By Application, By Specimen, By End-use, By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.28円
イムノアッセイの市場規模、シェア、動向分析レポート:製品別、技術別、用途別、検体別、最終用途別、地域別、セグメント予測、2024年~2030年
出版日: 2023年12月29日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

イムノアッセイ市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界のイムノアッセイ市場規模は2030年までに344億7,000万米ドルに達する見込みです。

2024年から2030年までのCAGRは3.60%で市場拡大が見込まれます。PoC迅速検査や自動イムノアッセイ分析装置のイントロダクションが市場成長を後押ししています。また、慢性疾患や感染症の増加が高い市場成長につながっています。

米国がん協会によると、2020年のがん患者/生存者数は推定1,690万人です。米国国立がん研究所2019年データによると、米国では約180万人のがん患者が診断されました。米国がん協会によると、2019年に米国でがんが原因で約606,880人が死亡しました。このように、がんと診断される症例数の増加がイムノアッセイの需要を促進しています。これは、今後数年間の市場成長を押し上げると予想されます。

さらに、感染症や予防対策に関する意識の高まりが、迅速診断検査製品への高い需要につながり、売上を伸ばしています。WHOによるWorld malaria report 2018の調査によると、メーカーは2017年にラテラルフローアッセイの売上高を2億7,600万と報告しています。また、2017年にサハラ以南のアフリカで約75.0%のマラリア症例がラテラルフローアッセイを用いて診断されたことも報告されています。

いくつかのスマートフォンベースの機器や関連ツールが次世代のポイントオブケア診断や検査機器として登場し、市場の成長を後押ししています。例えば、自律型キャピラリーマイクロ流体チップと組み合わせたスマートフォンアプリケーションは、心筋梗塞における心筋トロポニンiの迅速検査に使用されています。このプラットフォームは、資源が限られた環境でも容易に使用でき、12分以内に検査結果を得ることができます。このように、新しい技術の進歩は予測期間中、市場をさらに牽引すると予想されます。

米国におけるAptioオートメーション付きAtellicaイムノアッセイソリューションの最初の導入は、2018年4月にシーメンスヘルスケアGmbHによって発表されました。この製品の目的は、米国で先進技術製品を普及させるために設計されました。2020年12月、Danaherの事業であるBeckman Coulterは、COVID-19抗原検出のための最初の高品質だけでなくスループットアッセイを発表し、正式名称はAccess SARS-CoV-2 Antigen assayとなった。2018年7月、Cygnus TechnologiesとGyros Protein Technologiesは、バイオ治療毒素を同定するイムノアッセイを製造するために提携しました。両社の戦略的提携は、主にバイオ分析ソリューションの提供とバイオ治療薬製造の効率化に重点を置く。

イムノアッセイ市場レポートハイライト

  • 酵素イムノアッセイ法(EIA)セグメントは、感染症や慢性疾患、食物アレルギー、薬物乱用などの検出で繰り返し使用されるため、2023年には63.39%の最大市場シェアを占めました。
  • 試薬・キットセグメントは、2023年に66.16%の最大シェアに貢献しました。大きな市場シェアは、感染症や自己免疫疾患の有病率の上昇に起因するイムノアッセイ試薬と診断キットの需要増に起因しています。
  • 用途別では、感染症検査分野が2023年に36.39%の最大市場シェアを占め、予測期間中に最も速いCAGRで成長すると予測されています。
  • 血液検体セグメントは2023年に43.11%の最大シェアを占めました。これは疾病発生の増加に起因し、様々な血液検査手順の需要を促進し、セグメントの成長を支えています。
  • 最終用途別では、病院分野が2023年に32.94%の収益シェアで市場を独占しました。病院と診療所は、病状の診断と治療のためのプライマリケアの場です。
  • 北米は、2023年に40.60%の収益シェアで最も高い収益を上げました。慢性疾患に関連する診断への需要の高まりと、技術的に高度な診断技術の利用可能性の増加が、予測期間中の市場成長を促進すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 慢性疾患や感染症の発生率の増加
    • ポイントオブケア診断の需要の増加
    • ポータブルで自動化されたイムノアッセイに対する需要の高まり
  • 市場促進要因
    • 検出下限値
    • イムノアッセイ技術に関連する制限
  • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析;要因別(政治・法律、経済・技術)
    • ポーターのファイブフォース分析
    • COVID-19感染症の影響分析

第4章 製品のビジネス分析

  • イムノアッセイ市場:製品の変動分析
  • 試薬とキット
    • 試薬およびキット市場、2018~2030年
    • ELISA試薬およびキット
    • 迅速検査試薬およびキット
    • ELISPOT試薬およびキット
    • ウェスタンブロット試薬およびキット
    • その他の試薬およびキット
  • 分析装置/機器
    • アナライザー/計測器市場、2018~2030年
    • オープンエンドシステム
    • クローズエンドシステム
  • ソフトウェアとサービス
    • ソフトウェアおよびサービス市場、2018~2030年

第5章 検体のビジネス分析

  • イムノアッセイ市場:検体の変動分析
  • 血液
  • 唾液
  • 尿
  • その他

第6章 技術のビジネス分析

  • イムノアッセイ市場:技術の変動分析
  • ラジオイムノアッセイ
  • 酵素イムノアッセイ法迅速検査
    • 化学発光イムノアッセイ法
    • 蛍光イムノアッセイ法
  • その他

第7章 最終用途のビジネス分析

  • イムノアッセイ市場:流通チャネルの変動分析
  • 病院
  • ホームケア
  • 専門クリニック
  • その他

第8章 最終用途のビジネス分析

  • イムノアッセイ市場:流通チャネルの変動分析
  • 病院
  • 血液銀行
  • 臨床検査室
  • 製薬会社およびバイオテクノロジー企業
  • 学術研究センター
  • その他

第9章 地域のビジネス分析

  • 地域別イムノアッセイ市場シェア、2023年および2030年
  • 北米
    • 北米イムノアッセイ市場、2018~2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州イムノアッセイ市場、2018~2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋免疫分析市場、2018~2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカイムノアッセイ市場、2018~2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA免疫分析市場、2018年から2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • イムノアッセイ市場シェア分析、2023年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 Global Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 5 Global Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 6 Global Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 7 Global Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 8 Global Immunoassays Market, by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 10 North America Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 North America Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 12 North America Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 13 North America Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 14 North America Immunoassays Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 U.S. Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 16 U.S. Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 17 U.S. Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 18 U.S. Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 19 U.S. Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 20 Canada Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 Canada Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 22 Canada Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 23 Canada Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 24 Canada Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 25 Europe Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Europe Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 27 Europe Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 28 Europe Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 29 Europe Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 30 Europe Immunoassays Market, by Country, 2018 - 2030 (USD Million)
  • Table 31 Germany Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Germany Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 33 Germany Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 34 Germany Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 35 Germany Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 36 UK Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 37 UK Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 38 UK Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 39 UK Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 40 UK Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 41 France Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 France Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 France Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 44 France Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 45 France Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 46 Spain Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 47 Spain Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 48 Spain Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 49 Spain Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 50 Spain Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 51 Italy Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 52 Italy Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 Italy Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 54 Italy Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 55 Italy Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 56 Denmark Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 Denmark Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 58 Denmark Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 59 Denmark Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 60 Denmark Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 61 Sweden Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 62 Sweden Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 63 Sweden Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 64 Sweden Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 65 Sweden Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 66 Norway Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 67 Norway Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 68 Norway Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 69 Norway Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 70 Norway Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Immunoassays Market, by Country, 2018 - 2030 (USD Million)
  • Table 77 South Korea Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 78 South Korea Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 79 South Korea Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 80 South Korea Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 81 South Korea Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 82 Thailand Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 83 Thailand Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 84 Thailand Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 85 Thailand Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 86 Thailand Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 87 Australia Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 88 Australia Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 89 Australia Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 90 Australia Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 91 Australia Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 92 China Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 93 China Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 94 China Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 95 China Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 96 China Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 97 Japan Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 98 Japan Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 99 Japan Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 100 Japan Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 101 Japan Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 102 India Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 103 India Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 104 India Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 105 India Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 106 India Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 107 Latin America Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 108 Latin America Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 109 Latin America Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 110 Latin America Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 111 Latin America Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 112 Latin America Immunoassays Market, by Country, 2018 - 2030 (USD Million)
  • Table 113 Brazil Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 114 Brazil Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 115 Brazil Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 116 Brazil Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 117 Brazil Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 118 Mexico Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 119 Mexico Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 120 Mexico Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 121 Mexico Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 122 Mexico Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 123 Argentina Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 124 Argentina Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 125 Argentina Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 126 Argentina Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 127 Argentina Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 132 Middle East & Africa Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 133 Middle East & Africa Immunoassays Market, by Country, 2018 - 2030 (USD Million)
  • Table 134 South Africa Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 135 South Africa Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 136 South Africa Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 137 South Africa Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 138 South Africa Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 143 Saudi Arabia Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 144 UAE Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 145 UAE Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 146 UAE Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 147 UAE Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 148 UAE Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)
  • Table 149 Kuwait Immunoassays Market, by Product, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Immunoassays Market, by Application, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Immunoassays Market, by Technology, 2018 - 2030 (USD Million)
  • Table 152 Kuwait Immunoassays Market, by End-use, 2018 - 2030 (USD Million)
  • Table 153 Kuwait Immunoassays Market, by Specimen, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Immunoassays Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2023
  • Fig. 15 Regional Marketplace: Key Takeaways
  • Fig. 16 Regional Outlook, 2023 & 2030
  • Fig. 17 North America Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 19 Canada Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 20 Europe Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 21 Germany Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 22 UK Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 23 France Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 24 Spain Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 25 Italy Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 26 Russia Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 27 Asia Pacific Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 28 Japan Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 29 China Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 30 India Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 31 Australia Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 32 South Korea Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 33 Singapore Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 34 Latin America Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 35 Brazil Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 37 Argentina Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 38 Middle East and Africa Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 39 South Africa Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 40 Saudi Arabia Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 41 UAE Immunoassays Market, 2018 - 2030 (USD Million)
  • Fig. 42 Global Immunoassays Market, for, Reagents & Kits 2018 - 2030 (USD Million)
  • Fig. 43 Global Immunoassays Market, for, ELISA Reagents & Kits 2018 - 2030 (USD Million)
  • Fig. 44 Global Immunoassays Market, for, Rapid Test Reagents & Kits 2018 - 2030 (USD Million)
  • Fig. 45 Global Immunoassays Market, for, ELISPOT Reagents & Kits 2018 - 2030 (USD Million)
  • Fig. 46 Global Immunoassays Market, for, Western Blot Reagents & Kits 2018 - 2030 (USD Million)
  • Fig. 47 Global Immunoassays Market, for, Other Reagents & Kits 2018 - 2030 (USD Million)
  • Fig. 48 Global Immunoassays Market, for, Analyzers/Instruments 2018 - 2030 (USD Million)
  • Fig. 49 Global Immunoassays Market, for, Open-ended Systems 2018 - 2030 (USD Million)
  • Fig. 50 Global Immunoassays Market, for, Closed-ended Systems 2018 - 2030 (USD Million)
  • Fig. 51 Global Immunoassays Market, for, Software & Services 2018 - 2030 (USD Million)
  • Fig. 52 Global Immunoassays Market, for, Radioimmunoassay (RIA) 2018 - 2030 (USD Million)
  • Fig. 53 Global Immunoassays Market, for, Enzyme Immunoassays (EIA) 2018 - 2030 (USD Million)
  • Fig. 54 Global Immunoassays Market, for, Chemiluminescence Immunoassays (CLIA) 2018 - 2030 (USD Million)
  • Fig. 55 Global Immunoassays Market, for, Fluorescence Immunoassays (FIA) 2018 - 2030 (USD Million)
  • Fig. 56 Global Immunoassays Market, for, Rapid Test2018 - 2030 (USD Million)
  • Fig. 57 Global Immunoassays Market, for, Others 2018 - 2030 (USD Million)
  • Fig. 58 Global Immunoassays Market, for, Therapeutic Drug Monitoring2018 - 2030 (USD Million)
  • Fig. 59 Global Immunoassays Market, for, Oncology2018 - 2030 (USD Million)
  • Fig. 60 Global Immunoassays Market, for, Cardiology2018 - 2030 (USD Million)
  • Fig. 61 Global Immunoassays Market, for, Endocrinology2018 - 2030 (USD Million)
  • Fig. 62 Global Immunoassays Market, for, Infectious Disease Testing2018 - 2030 (USD Million)
  • Fig. 63 Global Immunoassays Market, for, Autoimmune Diseases 2018 - 2030 (USD Million)
  • Fig. 64 Global Immunoassays Market, for, Others 2018 - 2030 (USD Million)
  • Fig. 65 Global Immunoassays Market, for, Blood 2018 - 2030 (USD Million)
  • Fig. 66 Global Immunoassays Market, for, Saliva 2018 - 2030 (USD Million)
  • Fig. 67 Global Immunoassays Market, for, Urine 2018 - 2030 (USD Million)
  • Fig. 68 Global Immunoassays Market, for, Other Specimens 2018 - 2030 (USD Million)
  • Fig. 69 Global Immunoassays Market, for, Hospitals 2018 - 2030 (USD Million)
  • Fig. 70 Global Immunoassays Market, for, Blood Banks 2018 - 2030 (USD Million)
  • Fig. 71 Global Immunoassays Market, for, Clinical Laboratories 2018 - 2030 (USD Million)
  • Fig. 72 Global Immunoassays Market, for, Pharmaceutical and Biotech Companies 2018 - 2030 (USD Million)
  • Fig. 73 Global Immunoassays Market, for, Academic Research Centers 2018 - 2030 (USD Million)
  • Fig. 74 Global Immunoassays Market, for, Others 2018 - 2030 (USD Million)
目次
Product Code: GVR-3-68038-066-8

Immunoassay Market Growth & Trends:

The global immunoassay market size is expected to reach USD 34.47 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.60% from 2024 to 2030. The introduction of PoC rapid tests and automated immunoassay analyzers is boosting market growth. In addition, the rising number of chronic and infectious diseases is leading to high market growth.

According to the American Cancer Society, there were an estimated 16.9 million cancer patients/survivors in 2020. Around 1.8 million cancer cases were diagnosed in the U.S., according to the National Cancer Institute 2019 data. According to the American Cancer Society, nearly 606,880 deaths occurred due to cancer in the U.S. in 2019. Thus, the rise in the number of cancer cases being diagnosed is driving the demand for immunoassays. This is expected to boost the market growth in the coming years.

Furthermore, growing awareness regarding infectious diseases and preventive measures has led to a high demand for rapid diagnostic test products, thereby increasing sales. Based on a survey by the WHO on the World malaria report 2018, manufacturers reported sales of 276 million for lateral flow assays in 2017. It also reported that around 75.0% of malaria cases were diagnosed using lateral flow assays in sub-Saharan Africa in 2017.

Several smartphone-based devices and associated tools have emerged as next-generation point-of-care diagnostics or testing devices, thereby boosting the market growth. For instance, a smartphone application combined with the autonomous capillary microfluidic chip is used for the rapid testing of cardiac troponin I in myocardial infarction. This platform can be easily used in resource-limited settings, providing test results within 12 minutes. Thus, novel technological advancements are anticipated to further drive the market over the forecast period.

The first implementation of the Atellica immunoassay solutions with Aptio automation in the United States was announced by Siemens Healthcare GmbH in April 2018. The objective of this product was designed to promote advanced technological products in the U.S. In December 2020, Beckman Coulter, a Danaher business, introduced its first high-quality as well as throughput assay for the COVID-19 antigen detection, officially named Access SARS-CoV-2 Antigen assay. In July 2018, Cygnus Technologies and Gyros Protein Technologies collaborated to produce immunoassay to identify biotherapeutic toxins. The two companies' strategic alliance will primarily focus on offering bioanalytical solutions and increasing biotherapeutics manufacturing efficiencies.

Immunoassay Market Report Highlights:

  • The enzyme immunoassays (EIA) segment held the largest market share of 63.39% in 2023, owing to their repeated usage in the detection of infectious and chronic diseases, food allergies, and drug abuse, among other applications.
  • The reagents and kits segment contributed to the largest share of 66.16% in 2023. A significant market share can be attributed to the increased demand for immunoassay reagents and diagnostic kits, owing to the rising prevalence of infectious and autoimmune diseases.
  • Based on application, the infectious diseases testing segment held the largest market share of 36.39% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period.
  • The blood specimen segment held the largest share of 43.11% in 2023 attributed to an increase in disease occurrence, which drives demand for different blood testing procedures, supporting segment growth.
  • Based on end-use, the hospitals segment dominated the market in 2023 with a revenue share of 32.94%. Hospitals and clinics are primary care settings for the diagnosis and treatment of medical conditions.
  • North America generated the highest revenue in 2023 with a 40.60% revenue share. The rise in demand for diagnostics related to chronic diseases and the increase in availability of technologically advanced diagnostic techniques are expected to propel market growth over the forecast period.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Rising incidence of chronic and infectious diseases
    • 3.3.2. Increasing demand for point-of-care diagnostics
    • 3.3.3. Growing demand for portable and automated immunoassays
  • 3.4. Market Drivers
    • 3.4.1. Lower detection limit
    • 3.4.2. Limitations associated with immunoassay techniques
  • 3.5. Market Restraint Analysis
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Immunoassay market: Product Movement Analysis
  • 4.2. Reagents & Kits
    • 4.2.1. Reagents & Kits Market, 2018 - 2030 (USD Million)
    • 4.2.2. ELISA Reagents & Kits
      • 4.2.2.1. ELISA Reagents & Kits Market, 2018 - 2030 (USD Million)
    • 4.2.3. Rapid Test Reagents & Kits
      • 4.2.3.1. Rapid Test Reagents & Kits Market, 2018 - 2030 (USD Million)
    • 4.2.4. ELISPOT Reagents & Kits
      • 4.2.4.1. ELISPOT Reagents & Kits Market, 2018 - 2030 (USD Million)
    • 4.2.5. Western Blot Reagents & Kits
      • 4.2.5.1. Western Blot Reagents & Kits Market, 2018 - 2030 (USD Million)
    • 4.2.6. Other Reagents & Kits
      • 4.2.6.1. Other Reagents & Kits Market, 2018 - 2030 (USD Million)
  • 4.3. Analyzers/Instruments
    • 4.3.1. Analyzers/Instruments Market, 2018 - 2030 (USD Million)
    • 4.3.2. Open Ended Systems
      • 4.3.2.1. Open Ended Systems & Kits Market, 2018 - 2030 (USD Million)
    • 4.3.3. Close Ended Systems
      • 4.3.3.1. Close Ended Systems Reagents & Kits Market, 2018 - 2030 (USD Million)
  • 4.4. Software & Services
    • 4.4.1. Software & Services Market, 2018 - 2030 (USD Million)

Chapter 5. Specimen Business Analysis

  • 5.1. Immunoassay Market: Specimen Movement Analysis
  • 5.2. Blood
    • 5.2.1. Blood Market, 2018 - 2030 (USD Million)
  • 5.3. Saliva
    • 5.3.1. Saliva Market, 2018 - 2030 (USD Million)
  • 5.4. Urine
    • 5.4.1. Urine Market, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Technology Business Analysis

  • 6.1. Immunoassay Market: Technology Movement Analysis
  • 6.2. Radioimmunoassay
    • 6.2.1. Radioimmunoassay Market, 2018 - 2030 (USD Million)
  • 6.3. Enzyme Immunoassays Rapid Test
    • 6.3.1. Enzyme Immunoassays Rapid Test Market, 2018 - 2030 (USD Million)
    • 6.3.2. Chemiluminescence Immunoassays
      • 6.3.2.1. Chemilluminescence Immunoassays Market, 2018 - 2030 (USD Million)
    • 6.3.3. Fluroscence Immunoassays
      • 6.3.3.1. Fluroscence Immunoassays Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

  • 7.1. Immunoassay Market: Distribution Channel Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.3. Homecare
    • 7.3.1. Homecare Market, 2018 - 2030 (USD Million)
  • 7.4. Specialty Clinics
    • 7.4.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. End-use Business Analysis

  • 8.1. Immunoassay Market: Distribution Channel Movement Analysis
  • 8.2. Hospitals
    • 8.2.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 8.3. Blood Banks
    • 8.3.1. Blood Banks Market, 2018 - 2030 (USD Million)
  • 8.4. Clinical Laboratories
    • 8.4.1. Clinical Laboratories Market, 2018 - 2030 (USD Million)
  • 8.5. Pharmaceutical and Biotech Companies
    • 8.5.1. Pharmaceutical and Biotech Companies Market, 2018 - 2030 (USD Million)
  • 8.6. Academic Research Centers
    • 8.6.1. Academic Research Centers Market, 2018 - 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

  • 9.1. Immunoassay Market Share By Region, 2023 & 2030
  • 9.2. North America
    • 9.2.1. North America Immunoassay market, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key Country Dynamics
      • 9.2.2.2. Target Disease Prevalence
      • 9.2.2.3. Competitive Scenario
      • 9.2.2.4. Regulatory Framework
      • 9.2.2.5. Reimbursement Scenario
      • 9.2.2.6. U.S. Immunoassay market, 2018 - 2030 (USD MILLION)
    • 9.2.3. Canada
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Target Disease Prevalence
      • 9.2.3.3. Competitive Scenario
      • 9.2.3.4. Regulatory Framework
      • 9.2.3.5. Reimbursement Scenario
      • 9.2.3.6. Canada Immunoassay market, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.2. Germany
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Target Disease Prevalence
      • 9.3.2.3. Competitive Scenario
      • 9.3.2.4. Regulatory Framework
      • 9.3.2.5. Reimbursement Scenario
      • 9.3.2.6. Germany Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.3. UK
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Target Disease Prevalence
      • 9.3.3.3. Competitive Scenario
      • 9.3.3.4. Regulatory Framework
      • 9.3.3.5. Reimbursement Scenario
      • 9.3.3.6. UK Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Target Disease Prevalence
      • 9.3.4.3. Competitive Scenario
      • 9.3.4.4. Regulatory Framework
      • 9.3.4.5. Reimbursement Scenario
      • 9.3.4.6. France Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Target Disease Prevalence
      • 9.3.5.3. Competitive Scenario
      • 9.3.5.4. Regulatory Framework
      • 9.3.5.5. Reimbursement Scenario
      • 9.3.5.6. Italy Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Target Disease Prevalence
      • 9.3.6.3. Competitive Scenario
      • 9.3.6.4. Regulatory Framework
      • 9.3.6.5. Reimbursement Scenario
      • 9.3.6.6. Spain Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Target Disease Prevalence
      • 9.3.7.3. Competitive Scenario
      • 9.3.7.4. Regulatory Framework
      • 9.3.7.5. Reimbursement Scenario
      • 9.3.7.6. Denmark Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Target Disease Prevalence
      • 9.3.8.3. Competitive Scenario
      • 9.3.8.4. Regulatory Framework
      • 9.3.8.5. Reimbursement Scenario
      • 9.3.8.6. Sweden Immunoassay market, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Target Disease Prevalence
      • 9.3.9.3. Competitive Scenario
      • 9.3.9.4. Regulatory Framework
      • 9.3.9.5. Reimbursement Scenario
      • 9.3.9.6. Norway Immunoassay market, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Immunoassay market, 2018 - 2030 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Competitive Scenario
      • 9.4.2.4. Regulatory Framework
      • 9.4.2.5. Reimbursement Scenario
      • 9.4.2.6. Japan Immunoassay market, 2018 - 2030 (USD Million)
    • 9.4.3. China
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Competitive Scenario
      • 9.4.3.4. Regulatory Framework
      • 9.4.3.5. Reimbursement Scenario
      • 9.4.3.6. China Immunoassay market, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Competitive Scenario
      • 9.4.4.4. Regulatory Framework
      • 9.4.4.5. Reimbursement Scenario
      • 9.4.4.6. India Immunoassay market, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Target Disease Prevalence
      • 9.4.5.3. Competitive Scenario
      • 9.4.5.4. Regulatory Framework
      • 9.4.5.5. Reimbursement Scenario
      • 9.4.5.6. South Korea Immunoassay market, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Target Disease Prevalence
      • 9.4.6.3. Competitive Scenario
      • 9.4.6.4. Regulatory Framework
      • 9.4.6.5. Reimbursement Scenario
      • 9.4.6.6. Australia Immunoassay market, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Target Disease Prevalence
      • 9.4.7.3. Competitive Scenario
      • 9.4.7.4. Regulatory Framework
      • 9.4.7.5. Reimbursement Scenario
      • 9.4.7.6. Thailand Immunoassay market, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Immunoassay market, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Competitive Scenario
      • 9.5.2.4. Regulatory Framework
      • 9.5.2.5. Reimbursement Scenario
      • 9.5.2.6. Brazil Immunoassay market, 2018 - 2030 (USD Million)
    • 9.5.3. Mexico
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Competitive Scenario
      • 9.5.3.4. Regulatory Framework
      • 9.5.3.5. Reimbursement Scenario
      • 9.5.3.6. Mexico Immunoassay market, 2018 - 2030 (USD Million)
    • 9.5.4. Argentina
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Competitive Scenario
      • 9.5.4.4. Regulatory Framework
      • 9.5.4.5. Reimbursement Scenario
      • 9.5.4.6. Argentina Immunoassay market, 2018 - 2030 (USD Million)
  • 9.6. MEA
    • 9.6.1. MEA Immunoassay market, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Competitive Scenario
      • 9.6.2.4. Regulatory Framework
      • 9.6.2.5. Reimbursement Scenario
      • 9.6.2.6. South Africa Immunoassay market, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Competitive Scenario
      • 9.6.3.4. Regulatory Framework
      • 9.6.3.5. Reimbursement Scenario
      • 9.6.3.6. Saudi Arabia Immunoassay market, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Competitive Scenario
      • 9.6.4.4. Regulatory Framework
      • 9.6.4.5. Reimbursement Scenario
      • 9.6.4.6. UAE Immunoassay market, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Competitive Scenario
      • 9.6.5.4. Regulatory Framework
      • 9.6.5.5. Reimbursement Scenario
      • 9.6.5.6. Kuwait Immunoassay market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant's overview
  • 10.2. Financial performance
  • 10.3. Participant categorization
    • 10.3.1. Market Leaders
    • 10.3.2. Immunoassay market Share Analysis, 2023
    • 10.3.3. Company Profiles
      • 10.3.3.1. Siemens Healthineers
      • 10.3.3.1.1. Company Overview
      • 10.3.3.1.2. Financial Performance
      • 10.3.3.1.3. Product Benchmarking
      • 10.3.3.1.4. Strategic Initiatives
      • 10.3.3.2. bioMerieux SA
      • 10.3.3.2.1. Company Overview
      • 10.3.3.2.2. Financial Performance
      • 10.3.3.2.3. Product Benchmarking
      • 10.3.3.2.4. Strategic Initiatives
      • 10.3.3.3. Abbott Laboratories
      • 10.3.3.3.1. Company Overview
      • 10.3.3.3.2. Financial Performance
      • 10.3.3.3.3. Product Benchmarking
      • 10.3.3.3.4. Strategic Initiatives
      • 10.3.3.4. Danaher Corporation (Beckman Coulter)
      • 10.3.3.4.1. Company Overview
      • 10.3.3.4.2. Financial Performance
      • 10.3.3.4.3. Product Benchmarking
      • 10.3.3.4.4. Strategic Initiatives
      • 10.3.3.5. Quidel Corporation
      • 10.3.3.5.1. Company Overview
      • 10.3.3.5.2. Financial Performance
      • 10.3.3.5.3. Product Benchmarking
      • 10.3.3.5.4. Strategic Initiatives
      • 10.3.3.6. Ortho Clinical Diagnostics
      • 10.3.3.6.1. Company Overview
      • 10.3.3.6.2. Financial Performance
      • 10.3.3.6.3. Product Benchmarking
      • 10.3.3.6.4. Sysmex Corporation
      • 10.3.3.7. Bio-Rad Laboratories, Inc.
      • 10.3.3.7.1. Company Overview
      • 10.3.3.7.2. Financial Performance
      • 10.3.3.7.3. Product Benchmarking
      • 10.3.3.7.4. Strategic Initiatives
      • 10.3.3.8. Becton, Dickinson, and Company
      • 10.3.3.8.1. Company Overview
      • 10.3.3.8.2. Financial Performance
      • 10.3.3.8.3. Product Benchmarking
      • 10.3.3.8.4. Strategic Initiatives
      • 10.3.3.9. F. Hoffmann-La Roche AG
      • 10.3.3.9.1. Company Overview
      • 10.3.3.9.2. Financial Performance
      • 10.3.3.9.3. Product Benchmarking
      • 10.3.3.9.4. Strategic Initiatives
      • 10.3.3.10. Thermo Fisher Scientific, Inc
      • 10.3.3.10.1. Company Overview
      • 10.3.3.10.2. Financial Performance
      • 10.3.3.10.3. Product Benchmarking
      • 10.3.3.10.4. Strategic Initiatives
      • 10.3.3.11. Sysmex Corporation
      • 10.3.3.11.1. Company Overview
      • 10.3.3.11.2. Financial Performance
      • 10.3.3.11.3. Product Benchmarking
      • 10.3.3.11.4. Strategic Initiatives
    • 10.3.4. Strategy Mapping
      • 10.3.4.1. Expansion
      • 10.3.4.2. Acquisition
      • 10.3.4.3. Collaborations
      • 10.3.4.4. Disease Type/Drug Class Launch
      • 10.3.4.5. Partnerships
      • 10.3.4.6. Others